Seres Therapeutics, Inc.
About Seres Therapeutics, Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $789.0K
- Net income
- $5.7M
- Total assets
- $138.2M
- Market cap
- $64.2M
- Operating margin
- -11910.1%
- Net margin
- 721.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $789.0K
- Operating expenses
- $94.8M
- Operating income
- -$94.0M
- Income tax
- $0
- Net income
- $5.7M
- EPS (basic)
- $0.64
- EPS (diluted)
- $0.64
Balance sheet
- Total assets
- $138.2M
- Current assets
- $49.4M
- Total liabilities
- $94.0M
- Current liabilities
- $19.3M
- Shareholders’ equity
- $44.2M
Cash flow
- Operating cash flow
- $1.1M
- Investing cash flow
- -$42.0K
- Financing cash flow
- $13.9M
- Net cash flow
- $15.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $64.2M
- P/E ratio
- 9.8
- EPS (diluted)
- $0.64
- Shares outstanding
- 10.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 26, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $5.7M in FY2025.
- Revenue declined 99% from FY2021 to FY2025.
- Trading 78% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 9.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Seres Therapeutics, Inc..
Write a review
News about Seres Therapeutics, Inc.
News & sentiment via Polygon.io
